Remus Pharmaceuticals Ltd
Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]
- Market Cap ₹ 1,167 Cr.
- Current Price ₹ 1,981
- High / Low ₹ 2,835 / 1,591
- Stock P/E 41.4
- Book Value ₹ 171
- Dividend Yield 0.08 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 11.6 times its book value
- Company has high debtors of 197 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | TTM | |
|---|---|---|
| 212 | 456 | |
| 185 | 417 | |
| Operating Profit | 28 | 39 |
| OPM % | 13% | 9% |
| 5 | 9 | |
| Interest | 0 | 1 |
| Depreciation | 1 | 1 |
| Profit before tax | 32 | 46 |
| Tax % | 18% | |
| 26 | 39 | |
| EPS in Rs | 36.51 | 50.71 |
| Dividend Payout % | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 2% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Sep 2024 | |
|---|---|---|
| Equity Capital | 1 | 6 |
| Reserves | 85 | 95 |
| 12 | 21 | |
| 159 | 100 | |
| Total Liabilities | 257 | 221 |
| 12 | 13 | |
| CWIP | 0 | 1 |
| Investments | 23 | 21 |
| 223 | 187 | |
| Total Assets | 257 | 221 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | |
|---|---|
| 4 | |
| -9 | |
| 24 | |
| Net Cash Flow | 19 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | |
|---|---|
| Debtor Days | 197 |
| Inventory Days | 95 |
| Days Payable | 208 |
| Cash Conversion Cycle | 84 |
| Working Capital Days | 68 |
| ROCE % |
Documents
Announcements
-
Structural Digital Database
25 April 2025 - Compliance certificate confirming insider trading regulations adherence for FY 2024-25, no non-compliance found.
-
Updates
19 April 2025 - Updated email and website addresses for company's Registrar and Share Transfer Agent.
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
18 April 2025 - Exemption from corporate governance report filing under Reg 27(2)
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
16 April 2025 - Quarterly share capital audit report submitted as per SEBI regulations.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
14 April 2025 - Submission of dematerialisation compliance certificate for March 2025 quarter.
Annual reports
Concalls
-
Nov 2024Transcript PPT REC
Busienss Overview:[1][2]
RPL and its group of companies specialize in marketing pharmaceutical products with expertise in Critical Care, Neurology, Cardiology, and Diabetic categories, and recently getting off-patent molecules in various dosage forms and in complex generics. Company gets finished pharmaceutical formulations manufactured on loan license or contract manufacturing